我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

莫索尼定对原发性高血压患者心率变异性和胰岛素敏感性的影响(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2003年第6期
页码:
519-521
栏目:
临床研究
出版日期:
2003-11-01

文章信息/Info

Title:
The effects of Moxonidine on heart rate variability and insulin sensitivity in hypertensive patients
作者:
查晓真; 牛小麟; 齐颖新; 宋安齐
西安交通大学第二医院心内科, 陕西 西安 710004
Author(s):
ZHA Xiao-zhen;  NIU Xiao-lin;  QI Ying-xin;  SONG An-qi
Department of Cardiology, Second Hospital of Xi’an Jiaotong Univercity, Xi’an, Shaanxi 710004, China
关键词:
高血压;  原发性; 莫索尼定; 心率变异性; 胰岛素敏感性
Keywords:
hypertension;  essential;  Moxonidine;  heart rate variability;  insulin sensitivity
分类号:
R541.3
DOI:
-
文献标识码:
A
摘要:
目的:探讨莫索尼定对原发性高血压(EH)患者的心率变异性(HRV)和胰岛素敏感性(IS)的影响。方法: 22例轻、中度EH患者每日口服莫索尼定0.2～0.4mg, 用药4周, 治疗前后分别行24 h动态心电图监测, 用时域分析法测定其HRV, 同时测定空腹血糖(FPG)、空腹血胰岛素水平(FINS)和胰岛素敏感性指数(ISI)。结果: EH患者治疗后的SBP、DBP 均明显降低(P<0.01) ,HRV 中SDNNI明显降低(P<0.01), SDNN, SDANN I 则明显增大(P<0.01), rMSSD, pNN50虽升高但变化不显著(P>0.05)。并发糖耐量减低的EH患者的FPG虽降低但变化不显著(P>0.05), FINS 显著降低(P<0.01), ISI显著提高(P<0.01); 糖耐量正常的EH 患者的FPG, FINS和ISI均无显著变化(P>0.05)。结论: 莫索尼定在有效降低血压的同时, 能改善EH患者的HRV, 并提高糖耐量降低的EH患者的胰岛素敏感性, 而对糖耐量正常的EH 患者的胰岛素敏感性无影响。
Abstract:
AIM: To investigate the effects of imidazoline-I1-receptor agonist Moxonidine on heart rate variability (HRV) and insulin sensitivity in patients with essential hypertension (EH). METHODS: 22 patients with mild to moderate EH were enrolled. A withdrawal period of 1～2 weeks was followed by 4 weeks of Moxonidine treatment (0.2～0.4 mg/d ). Before and after the treatment, ambulatory 24-hour holtermonitor records were obtained in all patients. We calculated the HRV of each record. At the same time, we measured fasting plasmaglucose (FPG) and fasting insulin (FINS) levels and the insulin sensitivity index (ISI). RESULTS: After Moxonidine treatment, blood pressure in EH patients was lowered significantly as compared with that before (P<0.01). In all patients, SDNNI was lowered significantly (P<0.01), SDNN and SDANNI were increased significantly (P<0.01), rMSSD and pNN 50 were increased, but not significantly (P>0.05). In the patients with impaired glucose tolerance (EH+IGT), the FPG was lowered, but not significantly (P>0.05). FINS was lowered and ISI was increased, very significantly (P<0.01). But no significant changes were found in patients with normal glucose tolerance (EH + NGT). CONCLUSION: Moxonidine can decrease blood pressure, improve HRV in patients with EH and has beneficial effect on improving insulin sensitivity in EH patients with impaired glucose tolerance, but not in patients with normal glucose tolerance.

参考文献/References

[1] Greenwood JP, Scott EM, Stoker JB, et al. Chronic I1-imidazoline agonism: sympathetic mechanisms in hypertension [J] . Hypertension, 2000, 35:1264-1269.

[2] Mayer G, Taberner PV. Effects of the imidazoline ligands efaroxan and KU 14R on blood glucose homeostasis in the mouse [J] . Eur J Pharmacol, 2002, 454(1):95-102.

[3] 张复生, 阎晓霞. 心律变异性研究发展概况 [J] . 心脏杂志, 2000, 12(2):122-125.

[4] Report of the expert committee on the diagnosis and classification of diabetes mellitus [J] . Diabetes Care, 1997, 20: 1183-1191.

[5] 李光伟, 潘孝仁, Bennett PH. 血浆葡萄糖、胰岛素比值是可靠的胰岛素敏感性指数吗? [J] . 中华心血管病杂志, 1996, 24:57- 62.

[6] 牛晓法, 黄叶莉, 汪嘉慧, 等. 老年高血压病并发冠心病心率变异性分析 [J] . 心脏杂志, 2001, 13(2):133-134.

[7] Guzzetti S, Dassi S, Pecis M, et al. Altered pattern of circadian neural control of heart period in mild hypertension [J] . J Hypertens, 1991, 9:831-838.

[8] 蒋赞利, 牛小麟, 王世臣. 原发性高血压患者胰岛素抵抗与心率变异的关系 [J] . 高血压杂志, 1998, 6:172-174.

[9] Stein PK, Bosner MS, Kleiger RE, et al. Heart rate variability: A measure of cardiac autonomic tone [J] . Am Heart J, 1994, 127:1376-1381

备注/Memo

备注/Memo:
收稿日期：2002-12-30.
更新日期/Last Update: 2003-11-01